Take two pills... (Psychiatric Times, Jan 20, 2017) | Promise and Perils of Pot (ScienceNews, Jan 16, 2017) | Witnessing fear can change your brain (ScienceDaily, Jan 12, 2017) | Tide of Dementia (Nature, Nov 13, 2016) | The Athletic Brain (the set pieces, Nov 13, 2016) | Beer decreases shyness! (BBC, Sep 29, 2016) | Can we see taste? (NPR, Sep 29, 2016) | Gene linked to Autism/Sociability (Science News, Sep 29, 2016) | Sleep deprivation hits hard (Science News, Aug 15, 2016) | The neuroscience of “cool” (Quartz, Aug 01, 2016) | Neuroscience of bullying (Medical News Today, Jul 11, 2016) | Can Neuroscience Change Our Minds? (Times Higher Education, Jul 11, 2016) | Ketamine metabolite may ease depression (ScienceNews, May 10, 2016) | How Zika kills brain cells (ScienceNews, May 09, 2016)

ACNP Spotlight


The 55th Annual Meeting closed with over 1700 members and scientific guests in attendance.  

55th Annual Meeting:
E-Poster Viewing
Program / Itinerary Planner

2017 New Members and Promotions - Please help us congratulate the 30 new Associate Members, 45 new Members, and 31 new ACNP Fellows. 


2017 New Website Editor Search (Submit by February 20th)

ACNP 2017 President's Letter- Dr. Anissa Abi-Dargham   

Neuropsychopharmacology ReviewsThe Immunology of Behavior — Exploring the Role of the Immune System in Brain Health and Illness   

The Critical Role of Nonhuman Primates in Medical Research

Minority Task Force Report on Initiatives  

Brief: Finding the Right Treatment for Depression

NPP PodcastNeuropsychopharmacology Reviews: The Immunology of Behavior—Exploring the Role of the Immune System in Brain Health and Illness

NIMH Directors Blog
NIDA Directors Blog

Are you receiving Neuropsychopharmacology e-alerts?
Sign up with your e-mail address to receive monthly table of contents alerts and keep informed with Neuropsychopharmacology news and announcements.  Each e-alert features the latest journal commentaries, circumspectives, original research and review articles. 

Neuro News Corner

Article- How scientists are hunting for a safer opioid painkiller

An opioid epidemic is upon us. Prescription painkillers such as fentanyl and morphine can ease terrible pain, but they can also cause addiction and death. The Centers for Disease Control and Prevention estimates that nearly 2 million Americans are abusing or addicted to prescription opiates. Politicians are attempting to stem the tide at state and national levels, with bills to change and monitor how physicians prescribe painkillers and to increase access to addiction treatment programs.

Those efforts may make access to painkillers more difficult for some. But pain comes to everyone eventually, and opioids are one of the best ways to make it go away.  

Morphine is the king of pain treatment. “For hundreds of years people have used morphine,” says Lakshmi Devi, a pharmacologist at the Ichan School of Medicine Mount Sinai in New York City.  “It works, it’s a good drug, that’s why we want it. The problem is the bad stuff.”

The “bad stuff” includes tolerance — patients have to take higher and higher doses to relieve their pain. Drugs such as morphine depress breathing, an effect that can prove deadly. They also cause constipation, drowsiness and vomiting. But “for certain types of pain, there are no medications that are as effective,” says Bryan Roth, a pharmacologist and physician at the University of North Carolina at Chapel Hill.  The trick is constructing a drug with all the benefits of an opioid painkiller, and few to none of the side effects. Here are three ways that scientists are searching for the next big pain buster, and three of the chemicals they’ve turned up.- Read More (Source - Science News, Images -VIPERFZK / ISTOCKPHOTO)



4/28/2017-Deadline to submit ACNP Travel Award applications.

5/9/2017-Deadline for submission of overall proposals by chairs (Panels, Mini-Panels, & Study Groups).

5/23/2017-Deadline for submission of individual presenter abstracts (Panels & Mini-Panels).

5/23/2017-Deadline for submission of disclosures by Study Group participants. 

5/26/2017-Deadline for chairs to review and finalize proposed sessions (Panels, Mini-Panels, & Study Groups).

6/28/2017-Deadline to submit Honorific Awards.

8/10/2017-Deadline to submit Poster Abstracts 



Welcome to the ACNP website

Welcome to the website of the American College of Neuropsychopharmacology (ACNP), a non-profit, professional society dedicated to advancing the scientific understanding of and facilitating communication about disorders of the brain and behavior in order to advance their prevention and treatment.


About the CoverWith a 2015 impact factor of 6.399 NPP ranks 12th of 140 Psychiatry journals, 11th of 253 Pharmacology and Pharmacy journals, and 21st of 252 Neuroscience journals. 68% of accepted articles are published online in less than 25 business days and in print in less than 111 business days. In 2016, all issues of Neuropsychopharmacology were published on or ahead of schedule. SUBMIT YOUR ARTICLE HERE.

NPP Reviews

NPP ReviewPublished each January as a special collection of review articles, the 2015 issue of NPPR addresses Neurodevelopment and the Origins of Brain Disorders.  Neuropsychopharmacology Reviews

Statement of Inclusion

The ACNP actively promotes and recognizes principles of fairness, equity, and social justice in relation to, and across, intersections of race, age, color, disability, faith, religion, ancestry, national origin, citizenship, sex, sexual orientation, social class, economic class, ethnicity, gender identity, gender expression, and all other identities represented among our diverse membership.